Neurocrine Biosciences, Inc. (NBIX)

Neurocrine Biosciences, Inc. (NBIX) Healthcare & Pipeline Overview

Neurocrine Biosciences, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of treatments for complex neurological, endocrine, and psychiatric disorders. Headquartered in San Diego, it leverages a robust pipeline, including its flagship tardive dyskinesia therapy, INGREZZA, and a diverse portfolio of clinical-stage candidates, addressing significant unmet medical needs across various therapeutic areas.

What Is the Investment Thesis for NBIX?

Neurocrine Biosciences, Inc. (NBIX) presents a research profile centered on its established commercial portfolio and a promising clinical pipeline addressing high-unmet-need neurological, endocrine, and psychiatric disorders. A primary value driver is INGREZZA, the company's lead asset for tardive dyskinesia, which contributes significantly to its revenue base. The company demonstrates strong financial health with a gross margin of 98.2% and a profit margin of 21.6%, reflecting efficient operations and the high-value nature of its specialized pharmaceutical products. Its market capitalization stands at $15.93 billion, with a P/E ratio of 25.8. Growth catalysts are primarily driven by the potential expansion of existing product indications and the successful advancement of its diverse clinical pipeline. Key programs like NBI-921352 for epilepsy and NBI-1065845 for major depressive disorder represent significant future revenue opportunities, contingent on positive clinical trial outcomes and regulatory approvals. Strategic collaborations with partners such as AbbVie Inc. also provide avenues for shared development costs and broader market access. However, the investment profile carries inherent risks typical of the biotechnology sector, including the high cost and uncertainty of drug development, potential clinical trial failures, intense competition, and regulatory hurdles. The company's future performance will largely depend on its ability to successfully navigate these challenges and bring its pipeline candidates to market.

Based on FMP financials and quantitative analysis

NBIX Key Highlights

• Market capitalization of $17.55B, reflecting its substantial presence in the biotechnology sector.
• A P/E ratio of 25.8, indicating investor valuation relative to its earnings.
• Achieved a robust profit margin of 21.6%, showcasing strong profitability from its commercialized products.
• Maintained an exceptional gross margin of 98.2%, highlighting efficient cost management in its pharmaceutical production.
• Exhibits a Beta of 0.34, suggesting lower volatility compared to the broader market.

Who Are NBIX's Competitors?

NBIX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NBIX's Key Strengths?

• Strong commercial portfolio led by INGREZZA for tardive dyskinesia, a market leader.
• Robust and diverse clinical pipeline targeting significant unmet medical needs in neurology, endocrinology, and psychiatry.
• High gross margin of 98.2% and profit margin of 21.6%, indicating efficient operations and product value.
• Strategic license and collaboration agreements with major pharmaceutical companies enhance R&D and market reach.

What Are NBIX's Weaknesses?

• Significant dependence on the commercial success of its lead product, INGREZZA.
• High research and development costs associated with a deep clinical pipeline.
• Exposure to regulatory risks and potential delays or failures in clinical trials.
• Does not currently offer a dividend, which may deter certain investor segments.

What Could Drive NBIX Stock Higher?

• Continued commercialization and market penetration of INGREZZA for tardive dyskinesia, driving sustained revenue growth.
• Clinical trial readouts for NBI-921352, a candidate for pediatric and adult focal epilepsy, which could unlock significant market opportunities.
• Progression and data announcements for NBI-827104, targeting rare pediatric epilepsy and essential tremor, advancing the pipeline in neurology.
• Clinical development milestones and potential data readouts for NBI-1065845 for major depressive disorder and NBI-118568 for schizophrenia, addressing large psychiatric markets.
• Leveraging existing license and collaboration agreements to accelerate development and expand the commercial reach of pipeline assets.

What Are the Key Risks for NBIX?

• Insider selling — insiders were net sellers of roughly $12.1M recently.
• Intense competition within the neurological, endocrine, and psychiatric therapeutic areas from both established pharmaceutical companies and emerging biotechs.
• Clinical trial failures or unexpected adverse events for pipeline candidates, leading to delays, increased costs, or abandonment of programs.
• Regulatory hurdles, including non-approval of new drugs or expanded indications by health authorities, impacting market access and revenue potential.
• Significant dependence on the continued commercial success and market acceptance of INGREZZA, making the company vulnerable to market shifts or competitive pressures.
• Challenges to intellectual property, such as patent expirations or legal disputes, which could erode market exclusivity and profitability.

What Are the Growth Opportunities for NBIX?

• Expansion of INGREZZA's Market Penetration and Potential New Indications: INGREZZA, Neurocrine's lead asset for tardive dyskinesia, represents a significant growth driver. The market for tardive dyskinesia treatments, while specialized, continues to have room for increased diagnosis and patient penetration. Ongoing efforts to educate healthcare providers and patients about the condition and available therapies can expand INGREZZA's addressable market. Furthermore, exploring additional indications for INGREZZA or related VMAT2 inhibitors could unlock new revenue streams. The success in this area relies on continued physician adoption, favorable reimbursement, and potential label expansions, contributing to sustained revenue growth in the mid-term. The global market for tardive dyskinesia treatments is projected to grow, offering a favorable environment for INGREZZA's continued commercial success.
• Advancement of Epilepsy Pipeline Candidates: Neurocrine Biosciences has two promising candidates in its epilepsy pipeline: NBI-921352 for pediatric and adult focal epilepsy, and NBI-827104 for rare pediatric epilepsy and essential tremor. Epilepsy represents a large and diverse market with significant unmet needs, particularly for drug-resistant forms and pediatric populations. Successful progression of these candidates through clinical trials, leading to regulatory approvals, would open access to multi-billion dollar markets. The development timelines for these assets typically span several years, with potential market entry in the late 2020s or early 2030s. Positive data readouts from ongoing or upcoming clinical trials for these programs would serve as crucial catalysts, validating the company's R&D strategy in a high-impact therapeutic area.
• Development of Major Depressive Disorder and Anhedonia Therapies: The company's pipeline includes NBI-1065845 for major depressive disorder (MDD) and NBI-1065846 for anhedonia in MDD. Major depressive disorder affects millions globally, and anhedonia, the inability to experience pleasure, is a particularly challenging symptom with limited effective treatments. The global antidepressant market is substantial, valued in the tens of billions of dollars, indicating a vast opportunity for novel therapies. Successful development and commercialization of these candidates could position Neurocrine as a significant player in the mental health space. Clinical trial success and subsequent regulatory approvals, likely in the early 2030s, are critical for realizing this growth opportunity, addressing a widespread condition with considerable patient need.
• Progression of Schizophrenia Treatment Candidate NBI-118568: Neurocrine Biosciences is developing NBI-118568 for the treatment of schizophrenia, a severe and chronic mental illness affecting a significant portion of the global population. The market for schizophrenia treatments is large, driven by the chronic nature of the disease and the need for improved efficacy and tolerability profiles over existing therapies. A novel and effective treatment could capture a substantial share of this multi-billion dollar market. The timeline for this opportunity depends on the successful completion of clinical trials and regulatory review, potentially leading to market entry in the early to mid-2030s. Positive clinical data would represent a major milestone, offering a new therapeutic option for patients and a significant growth avenue for the company.
• Leveraging Strategic License and Collaboration Agreements: Neurocrine Biosciences has established numerous partnerships with companies like Takeda Pharmaceutical Company Limited, AbbVie Inc., and Idorsia Pharmaceuticals Ltd. These collaborations are crucial for sharing development risks, accessing broader research capabilities, and potentially expanding the commercial reach of its products and pipeline candidates. For instance, agreements can facilitate co-development, co-commercialization, or out-licensing of assets in specific territories or for particular indications, thereby accelerating market access and diversifying revenue streams. These partnerships provide a strategic advantage by pooling resources and expertise, allowing Neurocrine to pursue a wider range of therapeutic programs and market opportunities than it might independently, contributing to long-term growth and stability.

What Opportunities Does NBIX Have?

• Potential expansion of existing product indications and increased market penetration for commercialized therapies.
• Successful advancement and regulatory approval of pipeline candidates for epilepsy, major depressive disorder, and schizophrenia.
• Leveraging strategic collaborations to accelerate development and commercialization in new geographic or therapeutic markets.
• Addressing large and growing markets for neurological and psychiatric disorders with novel, differentiated therapies.

What Threats Does NBIX Face?

• Intense competition from other pharmaceutical and biotechnology companies developing similar treatments.
• Risk of clinical trial failures, which can lead to significant financial losses and reputational damage.
• Challenges to intellectual property, including patent expirations or legal disputes.
• Changes in healthcare policy, reimbursement landscapes, or regulatory requirements impacting drug pricing and market access.

What Are NBIX's Competitive Advantages?

• Proprietary drug pipeline and extensive intellectual property protection for its commercialized products and investigational candidates.
• Specialized focus and deep expertise in complex neurological, endocrine, and psychiatric disorders, addressing niche markets with high barriers to entry.
• Established commercial infrastructure and market presence with approved and actively marketed products like INGREZZA.
• Strategic collaboration agreements with major pharmaceutical companies, providing access to additional resources, expertise, and broader market reach.
• Significant regulatory hurdles and high research and development costs inherent in pharmaceutical development, deterring new entrants.

What Does NBIX Do?

Neurocrine Biosciences, Inc., established in 1992 and headquartered in San Diego, California, is a specialized biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics for a range of challenging neurological, endocrine, and psychiatric disorders. The company has evolved into a key player in its niche, focusing on conditions with significant unmet medical needs. Its commercial portfolio is anchored by INGREZZA (valbenazine), a VMAT2 inhibitor that serves as its lead asset for the treatment of tardive dyskinesia, a movement disorder characterized by involuntary, repetitive body movements. Beyond INGREZZA, Neurocrine Biosciences offers other critical therapies. These include ONGENTYS (opicapone), a catechol-O-methyltransferase inhibitor, which acts as an adjunct to levodopa/DOPA decarboxylase inhibitors for managing Parkinson's disease symptoms. In the endocrine space, the company provides ORILISSA (elagolix) for the management of moderate to severe pain associated with endometriosis in women, and ORIAHNN (elagolix and estradiol and norethindrone acetate capsules; co-packaged with elagolix capsules) as a non-surgical oral medication for heavy menstrual bleeding linked to uterine fibroids in pre-menopausal women. The company maintains a robust and diverse clinical development pipeline aimed at addressing various high-impact conditions. Key product candidates include NBI-921352, which is being investigated for treating pediatric patients and adult focal epilepsy indications, and NBI-827104, targeting rare pediatric epilepsy and essential tremor. Furthermore, Neurocrine Biosciences is advancing NBI-1065845 for major depressive disorder, NBI-1065846 specifically for treating anhedonia within major depressive disorder, and NBI-118568 for schizophrenia. To bolster its research and development capabilities and expand its market reach, Neurocrine Biosciences has established strategic license and collaboration agreements with several prominent pharmaceutical and biotech firms, including Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. This comprehensive approach, combining internal innovation with external partnerships, underscores Neurocrine Biosciences' commitment to delivering novel therapeutic solutions to patients worldwide.

What Products and Services Does NBIX Offer?

• Discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders.
• Offers INGREZZA, a VMAT2 inhibitor, as its lead asset for treating tardive dyskinesia.
• Commercializes ONGENTYS for Parkinson's disease as an adjunct therapy.
• Provides ORILISSA for the management of moderate to severe endometriosis pain.
• Markets ORIAHNN as a non-surgical oral medication for heavy menstrual bleeding associated with uterine fibroids.
• Develops clinical-stage candidates for pediatric and adult focal epilepsy (NBI-921352) and rare pediatric epilepsy/essential tremor (NBI-827104).
• Advances pipeline programs for major depressive disorder (NBI-1065845), anhedonia in MDD (NBI-1065846), and schizophrenia (NBI-118568).
• Engages in strategic license and collaboration agreements with various pharmaceutical partners.

How Does NBIX Make Money?

• Generates revenue primarily from the sales of its commercialized pharmaceutical products, including INGREZZA, ONGENTYS, ORILISSA, and ORIAHNN.
• Invests significantly in internal research and development to discover and advance novel drug candidates for neurological, endocrine, and psychiatric disorders.
• Forms strategic license and collaboration agreements with other pharmaceutical companies to share development costs, expand market reach, and access complementary expertise.
• Focuses on developing therapies for conditions with high unmet medical needs, allowing for premium pricing and strong market positioning upon approval.

What Industry Does NBIX Operate In?

Neurocrine Biosciences, Inc. operates within the highly specialized and competitive biotechnology industry, specifically focusing on the development and commercialization of pharmaceuticals for neurological, endocrine, and psychiatric disorders. This segment of the healthcare sector is characterized by significant R&D investment, long development timelines, and stringent regulatory pathways. The market for central nervous system (CNS) and endocrine therapies is substantial and growing, driven by an aging global population, increasing diagnosis rates, and a persistent demand for more effective and safer treatment options. Neurocrine Biosciences positions itself as an innovator in these areas, particularly with its lead product INGREZZA for tardive dyskinesia and other commercialized therapies like ONGENTYS for Parkinson's and ORILISSA/ORIAHNN for women's health. The competitive landscape includes large pharmaceutical companies with broader portfolios and numerous smaller biotech firms vying for market share in specific therapeutic niches. Neurocrine's strategy involves leveraging its deep understanding of these complex disorders, maintaining a robust pipeline, and forming strategic collaborations to sustain its competitive edge and address critical unmet medical needs.

Who Are NBIX's Key Customers?

• Patients suffering from neurological disorders such as tardive dyskinesia, Parkinson's disease, and epilepsy.
• Women experiencing endocrine disorders like endometriosis pain and heavy menstrual bleeding associated with uterine fibroids.
• Individuals affected by psychiatric disorders, including major depressive disorder, anhedonia, and schizophrenia.
• Healthcare providers, including neurologists, psychiatrists, gynecologists, and primary care physicians, who prescribe their specialized medications.
• Hospitals, clinics, and pharmacies that stock and dispense Neurocrine Biosciences' therapeutic products.

Net sellingInsider Activity

Over the past six months, Neurocrine Biosciences, Inc. insiders filed 30 SEC Form 4 transactions — 23 sales and 7 purchases. On net that is roughly 77K shares disposed (about $12.1M), a signal worth weighing alongside the fundamentals.

NBIX Valuation & Market Position

With a $17.55B market cap, Neurocrine Biosciences, Inc. sits in the large-cap segment of the market. Relative to its peer group, NBIX's quantitative score of 94/100 is above the peer average of 50/100.

ROE 22%Key Financial Metrics

Return on equity for Neurocrine Biosciences, Inc. stands at 21.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 13.6%, showing how much profit it generates from its asset base. NBIX trades at a trailing price-to-earnings ratio of 25.84, above the Healthcare sector average of ~23x. Its free cash flow yield is 4.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.93 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.9%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 5/9Financial Health

Neurocrine Biosciences, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 8.83 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Neurocrine Biosciences, Inc. revenue of about $3.73B for fiscal 2026, with EPS near $7.72. The estimate reflects 17 contributing analysts.

Company Profile

Neurocrine Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Kyle W. Gano. NBIX has traded publicly since 1996.

NBIX Financials

NBIX Latest News

NBIX Analyst Consensus

NBIX MoonshotScore

Latest Neurocrine Biosciences, Inc. Analysis

Neurocrine Biosciences, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources